Stay updated on KD025 Efficacy and Safety in cGVHD Clinical Trial
Sign up to get notified when there's something new on the KD025 Efficacy and Safety in cGVHD Clinical Trial page.
Latest updates to the KD025 Efficacy and Safety in cGVHD Clinical Trial page
- Check7 days agoChange DetectedThe latest update on December 12, 2024, includes the posting of results for a study involving belumosudil, detailing various treatment arms, response definitions, and participant assessments over a maximum duration of 40.5 months for adults and 27.6 months for adolescents, while previous entries regarding study locations and specific endpoints have been removed.SummaryDifference64%
- Check14 days agoChange DetectedThe website has updated the contact details section for the study, clarifying that it now provides information for individuals who can answer questions about joining the study, along with the study's location.SummaryDifference2%
- Check21 days agoNo Change Detected
- Check28 days agoChange DetectedSeveral links related to rare diseases and clinical studies have been removed, including specific disease pages and resources from NIH and PubMed.SummaryDifference4%
- Check36 days agoChange DetectedThe website has been updated to version 2.12.2, with new additions including several disease pages, links to PubMed articles, and a new data download feature.SummaryDifference4%
- Check50 days agoChange DetectedThe website has been updated from version 2.12.0 to 2.12.1.SummaryDifference0.4%
- Check57 days agoChange DetectedThe website has been updated from version 2.11.2 to 2.12.0, indicating a new release with potential improvements or features.SummaryDifference0.5%
Stay in the know with updates to KD025 Efficacy and Safety in cGVHD Clinical Trial
Enter your email address, and we'll notify you when there's something new on the KD025 Efficacy and Safety in cGVHD Clinical Trial page.